Competition Law and Healthcare Data Monopolies

1. Introduction

Healthcare data monopolies arise when a healthcare undertaking, digital-health platform, hospital network, insurer, electronic health-record provider, health-information exchange, pharmaceutical-data company, or other intermediary obtains substantial control over a strategically important body of health-related data.

Healthcare data can include:

electronic health records;

diagnostic information;

prescription data;

claims information;

laboratory results;

patient histories;

genomic information;

healthcare-provider data;

treatment outcomes;

health-insurance information;

healthcare purchasing patterns;

clinical-trial information;

aggregated population-health data.

The competition-law problem does not arise merely because one organisation possesses a large amount of data. Data becomes particularly important from an antitrust perspective when control over it creates or reinforces market power, entry barriers, exclusionary advantages, or the ability to discriminate against competitors.

The central competition question is:

Can control over healthcare data be used to prevent actual or potential competitors from competing effectively?

2. Healthcare Data as an Economic Asset

Healthcare data possesses several characteristics that can generate market power.

A. Scale

A large dataset may contain information accumulated over millions of patient interactions.

B. Scope

Data can cover multiple dimensions:

age;

treatment;

diagnosis;

medication;

outcomes;

location;

insurance;

provider behaviour.

C. Historical depth

Longitudinal patient information can be difficult for new entrants to reproduce.

D. Network effects

More patients can generate more data.

More data can improve:

algorithms;

diagnosis;

prediction;

research;

personalised services.

Better services attract more patients.

This produces:

Users → Data → Better algorithms → Better services → More users → More data.

E. Switching costs

Healthcare providers may find it difficult to move:

patient records;

workflows;

integrations;

analytics;

historical information

from one platform to another.

3. Data Monopoly Does Not Automatically Mean Antitrust Violation

An important distinction must be maintained.

A company may possess a very large dataset without unlawfully monopolising a market.

Competition law generally asks:

What is the relevant market?

Does the undertaking possess substantial market power or dominance?

Is the data strategically important to competition?

Is the undertaking engaging in exclusionary or exploitative conduct?

Are competitors actually or potentially foreclosed?

Are there legitimate efficiencies or regulatory justifications?

Therefore:

Data concentration is a potential source of market power, not automatically an abuse of dominance.

4. Relevant Healthcare Data Markets

Healthcare data can support several distinct markets.

1. Electronic health-record services

Providers purchase software and infrastructure for storing and managing patient records.

2. Health-data analytics

Companies analyse healthcare data for:

research;

risk assessment;

population health;

pharmaceutical development.

3. Healthcare advertising

Patient or provider information may be used for targeted advertising.

4. Clinical decision-support systems

Data can improve predictive and clinical technologies.

5. Pharmaceutical research

Patient and clinical data can have substantial value for drug development.

6. Insurance analytics

Claims and treatment data can influence underwriting and risk analysis.

7. Health-information exchange

Data intermediaries may connect hospitals, physicians, insurers and laboratories.

A single undertaking may operate across several of these markets.

5. Theories of Competitive Harm

Healthcare data monopolisation can generate several theories of harm.

A. Refusal to provide access

A dominant undertaking may deny competitors access to important data.

B. Discriminatory access

The platform may provide favourable data access to affiliated businesses.

C. Data foreclosure

The undertaking may acquire data and prevent rivals from obtaining comparable datasets.

D. Self-preferencing

A platform may use data from participants to favour its own competing products.

E. Tying

Access to data may be conditioned on purchasing another service.

F. Exclusive contracts

Healthcare providers may be prevented from sharing data with competing platforms.

G. Data aggregation

The undertaking may combine data from multiple markets to strengthen its position.

H. Mergers

Acquisition of another healthcare-data provider can eliminate an important potential competitor.

6. FTC v. Indiana Federation of Dentists

FTC v. Indiana Federation of Dentists, 476 U.S. 447 (1986)

This is one of the most useful healthcare-information cases.

Dentists collectively refused to provide dental X-rays to insurers.

The Supreme Court treated the collective withholding of information as conduct capable of harming competition.

Significance for healthcare data monopolies

The case demonstrates that control over healthcare information can have competitive significance.

A healthcare-data platform could create competition concerns if participating providers collectively prevent rival insurers, healthcare platforms or other competitors from obtaining information necessary for effective competition.

The important distinction is between:

legitimate privacy restrictions; and

strategically motivated exclusion from information.

7. United States v. U.S. Gypsum

United States v. U.S. Gypsum Co., 438 U.S. 422 (1978)

U.S. Gypsum is an important authority concerning the competitive significance of information exchanges.

The case demonstrates that the exchange of strategically important information between competitors can raise antitrust concerns depending upon the circumstances.

Application to healthcare data

Healthcare data platforms may have access to information concerning:

prices;

reimbursement rates;

capacity;

service volumes;

planned expansion;

contracts.

If competitors obtain strategically sensitive information through a common data platform, uncertainty between competitors may be reduced.

Thus, a healthcare-data monopoly can potentially create both:

data-exclusion risks

and

data-coordination risks.

8. FTC v. Surescripts

FTC v. Surescripts, FTC File No. 101-0002

The Surescripts proceedings are particularly relevant because they involved important electronic-prescription infrastructure.

The FTC challenged conduct involving contractual arrangements and exclusionary strategies affecting competition in electronic prescription services.

Importance

Surescripts illustrates how control over healthcare information infrastructure can produce network-based market power.

The more healthcare providers participate in a network, the more valuable the network becomes.

A dominant healthcare-data intermediary can therefore potentially become a competitive bottleneck.

The case is especially relevant to:

interoperability;

exclusive arrangements;

network effects;

switching costs;

access to healthcare information infrastructure.

9. United States v. Microsoft

United States v. Microsoft Corp., 253 F.3d 34 (D.C. Cir. 2001)

Microsoft is not a healthcare case, but it is highly relevant to the technological structure of healthcare-data monopolies.

The case addressed Microsoft's use of control over an important technological platform to disadvantage competing technologies.

Healthcare application

A dominant healthcare-data platform might similarly control:

APIs;

data formats;

interoperability;

authentication;

integration tools.

It could potentially make competing healthcare applications more difficult to operate by restricting interoperability.

Thus, control over technical interfaces can reinforce control over data.

10. Bronner and Refusal to Provide Access

Oscar Bronner GmbH & Co. KG v Mediaprint, Case C-7/97

Bronner is a leading European authority on refusal-to-deal and essential-facilities principles.

The Court adopted a demanding standard before imposing an obligation on a dominant company to provide access to infrastructure.

Healthcare-data application

A healthcare-data provider might control:

an indispensable database;

an interoperability system;

a critical exchange;

a unique patient-data infrastructure.

A competitor could argue that access is essential.

However, not every commercially valuable database constitutes an essential facility.

Questions include:

Can the competitor obtain the data elsewhere?

Can a comparable database be created?

Is access genuinely indispensable?

Would refusal eliminate effective competition?

Is there an objective justification?

11. IMS Health and Data/Information Infrastructure

IMS Health GmbH & Co. OHG v NDC Health GmbH & Co. KG, Cases C-418/01 and C-7/01

The IMS Health litigation is particularly significant for the intersection between information structures and market power.

It involved the use of a pharmaceutical-sales information system and the question of access to an information structure protected by intellectual-property rights.

The Court applied demanding conditions before compulsory access could be required.

Relevance to healthcare data monopolies

IMS Health demonstrates that:

Control over a commercially important information structure does not automatically create a duty to license or disclose it.

At the same time, where the stringent conditions for exceptional access are satisfied, refusal may potentially become abusive.

This is directly relevant to proprietary healthcare databases.

12. Microsoft and Data Interoperability

The Microsoft doctrine also becomes relevant where healthcare-data monopolies control interoperability.

Consider:

Dominant EHR → proprietary API → competing healthcare application

If the dominant platform restricts interoperability in a way that substantially forecloses competitors, competition authorities may examine whether the technical restriction constitutes exclusionary conduct.

This is particularly important because healthcare providers may face enormous switching costs when changing EHR systems.

13. Google Shopping and Self-Preferencing

Google Shopping, Case T-612/17

Google Shopping provides a useful analogy for healthcare-data platforms.

The case concerned Google's treatment of its own comparison-shopping service within its search ecosystem.

Healthcare application

Imagine a healthcare-data platform that operates:

a health-data marketplace;

an analytics service;

a clinical decision-support product.

If the platform uses its control over data access or search rankings to favour its own healthcare products, competitors may face discriminatory competitive conditions.

The legal question would concern the platform's dominance, conduct and effects rather than self-preferencing alone.

14. Google Android and Ecosystem Leveraging

Google Android, Case T-604/18

The Android litigation demonstrates how a dominant digital ecosystem can potentially use contractual or technical arrangements to reinforce its position across related markets.

Healthcare data platforms can have similar ecosystem structures:

EHR → data exchange → analytics → clinical software → advertising → insurance services.

If a dominant platform uses control at one level to strengthen its position in another, competition authorities may examine potential leveraging.

15. American Express and Data-Sided Markets

Ohio v. American Express Co., 585 U.S. 529 (2018)

American Express is useful for understanding two-sided markets.

Healthcare-data platforms can similarly connect multiple participant groups:

patients;

hospitals;

physicians;

insurers;

laboratories;

technology providers.

The platform may derive value from the interaction between these sides.

Consequently, competition analysis may need to account for effects across the platform rather than considering only one group.

16. North Carolina Dental and Competitor-Controlled Governance

North Carolina State Board of Dental Examiners v. FTC, 574 U.S. 494 (2015)

The case concerned regulatory authority exercised by market participants.

Healthcare-data relevance

Suppose competing hospitals and physicians jointly control the governance of an important healthcare-data exchange.

They may have incentives to create:

restrictive standards;

discriminatory access conditions;

exclusionary certification requirements.

The case illustrates the broader risk associated with allowing active market participants to control structures that determine access to markets.

17. Phoebe Putney and Healthcare Concentration

FTC v. Phoebe Putney Health System, 568 U.S. 216 (2013)

Phoebe Putney concerned healthcare-market concentration and the state-action doctrine.

It is relevant to data monopolies because healthcare-data concentration can accompany healthcare-service concentration.

For example:

Hospital merger → larger patient base → larger dataset → stronger analytics → greater competitive advantage.

A merger may therefore have competitive consequences beyond the conventional hospital-service market.

18. Data Advantages and Barriers to Entry

A large healthcare-data incumbent may enjoy an advantage because new entrants cannot reproduce its dataset quickly.

This can create an information-based entry barrier.

For example:

The resulting competitive advantage can be particularly important for AI-based healthcare products.

19. Healthcare Data and Artificial Intelligence

AI intensifies the importance of healthcare data.

AI systems may require enormous datasets for:

diagnosis;

medical imaging;

clinical prediction;

drug discovery;

personalised treatment;

risk prediction.

A dominant healthcare-data platform may therefore obtain an advantage in AI markets.

This can produce a data → AI → data feedback loop:

More data → better AI → more users → more data.

Competition authorities may therefore examine whether access to data becomes a structural barrier to AI competition in healthcare.

20. Data Portability

Data portability can reduce market power by making switching easier.

If healthcare providers can easily transfer:

patient records;

clinical histories;

laboratory results;

transaction records;

provider data;

between platforms, incumbent data monopolies may face stronger competitive pressure.

Conversely, artificial technical barriers can increase lock-in.

Thus, portability has both:

a privacy/data-governance dimension, and

a competition dimension.

21. Interoperability

Interoperability is closely connected to data portability.

A healthcare-data monopoly may control:

API access;

authentication;

data formats;

patient-matching systems;

integration certification.

If interoperability is restricted, rival platforms may be unable to offer equivalent services.

The competition problem becomes more serious where:

the incumbent is dominant;

interoperability is commercially indispensable;

rivals cannot reasonably reproduce the interface;

exclusion materially harms competition.

22. Exclusive Data Agreements

A dominant healthcare platform may enter into agreements requiring hospitals or physicians to provide data exclusively to it.

Such arrangements may create foreclosure if competitors cannot obtain comparable information elsewhere.

However, exclusivity can sometimes produce legitimate efficiencies, such as:

investment in data infrastructure;

cybersecurity;

integration costs;

quality assurance.

Therefore, the assessment should consider:

duration;

scope;

market coverage;

alternatives;

foreclosure;

efficiencies.

23. Tying and Bundling

A healthcare-data provider could potentially require users to purchase multiple services together.

For example:

Access to the data platform requires purchase of the provider's analytics software.

Or:

Access to an EHR network requires use of the provider's affiliated cloud service.

Potential competition concerns include:

foreclosure of rival analytics firms;

increased switching costs;

leveraging of dominance;

raising competitors' costs.

24. Discriminatory Data Access

A healthcare-data monopoly may provide:

rapid API access to its affiliates;

delayed access to competitors;

cheaper data access to related companies;

superior technical support to affiliated businesses.

This creates a possible non-discrimination issue.

Competition law may be particularly concerned where the dominant undertaking both:

controls the data infrastructure; and

competes in downstream markets using that infrastructure.

25. Privacy and Competition Law

Healthcare data is unusually sensitive.

Consequently, competition law must not be interpreted as requiring unrestricted disclosure of patient information.

A refusal to disclose data may be legitimate where disclosure would violate:

patient confidentiality;

data-protection obligations;

cybersecurity requirements;

informed-consent rules;

medical ethics.

The competition question is therefore not simply:

"Did the company refuse to share data?"

It is:

"Was the refusal objectively justified, or was privacy/security invoked as a pretext for excluding competitors?"

26. Data Quality as a Competitive Variable

Competition is not limited to price.

Healthcare-data platforms may compete on:

accuracy;

completeness;

timeliness;

interoperability;

security;

reliability.

A dominant platform could theoretically reduce data quality after competitors are weakened.

This means competition authorities should consider quality effects alongside prices.

27. Exploitative Data Practices

Competition law may also examine whether a dominant platform imposes unfair conditions concerning data.

Examples could include:

excessive contractual restrictions;

unreasonable data-use conditions;

excessive charges for access;

discriminatory terms.

However, not every burdensome data policy constitutes an abuse of dominance.

The conduct must be analysed within the applicable competition-law framework.

28. Merger Control and Data Monopolies

Mergers are especially important.

Consider:

Transaction A

Large EHR company acquires health-data analytics firm.

Transaction B

Hospital network acquires a health-information exchange.

Transaction C

Insurance-data company acquires a clinical-data platform.

Transaction D

Pharmaceutical-data company acquires an AI healthcare startup.

The competitive analysis should examine:

data concentration;

loss of potential competition;

foreclosure;

interoperability;

innovation;

access to essential inputs;

ecosystem effects.

29. Indian Competition Act, 2002

The Indian framework is principally built around:

Section 3 — Anti-competitive agreements

Potential healthcare-data issues include:

exclusive data-sharing agreements;

information exchanges between competitors;

collective exclusion;

discriminatory arrangements.

Section 4 — Abuse of dominant position

Potential conduct includes:

denial of market access;

unfair or discriminatory conditions;

discriminatory pricing;

leveraging;

exclusionary practices.

Merger control

Transactions involving major healthcare-data businesses can also require examination under India's merger-control framework where the applicable statutory thresholds and requirements are satisfied.

30. Indian Competition-Law Relevance of Platform Cases

Indian competition law increasingly has to address digital ecosystems where:

data + network effects + technology + market access

combine to create market power.

The principles developed in Indian cases involving digital platforms, technology markets and dominance can therefore inform healthcare-data analysis even where a particular case does not involve medical data.

The statutory question remains whether the undertaking has dominance in a relevant market and whether its conduct constitutes abuse under Section 4.

31. Main Case-Law Set

32. Competition Risks in a Healthcare Data Monopoly

The overall risk structure can be summarised as:

Input foreclosure

Competitors cannot obtain equivalent healthcare data.

Customer foreclosure

Healthcare providers are locked into the dominant platform.

Innovation foreclosure

New AI and healthcare technologies cannot obtain sufficient data to develop.

Interoperability foreclosure

Rivals cannot connect effectively to the incumbent system.

Data leveraging

Data collected in one market is used to dominate another.

Self-preferencing

The platform uses proprietary data to favour affiliated products.

Exclusivity

Healthcare providers are prevented from supplying competing platforms.

Algorithmic discrimination

Algorithms systematically disadvantage competing providers.

Network-effect reinforcement

The incumbent's large user base produces additional data, which further strengthens its position.

33. Possible Competition-Law Remedies

Where unlawful conduct is established, authorities could consider:

Access remedies

Reasonable and non-discriminatory access to relevant infrastructure.

Data portability

Allowing users to transfer their information between platforms, subject to privacy requirements.

Interoperability

Open and technically reasonable APIs.

Non-discrimination

Equivalent access conditions for affiliated and unaffiliated businesses.

Data firewalls

Preventing sensitive information collected from customers from being improperly used by downstream competitors.

Contractual restrictions

Limiting excessive exclusivity arrangements.

Transparency

Greater transparency concerning data-access and ranking mechanisms.

Structural remedies

In exceptional cases, separation of data infrastructure from competing downstream businesses may be considered.

34. Important Limitation: Data Is Not Necessarily an Essential Facility

A recurring mistake in healthcare-data antitrust analysis is assuming:

"The database is unique, therefore competitors must receive access."

That conclusion does not automatically follow.

Competition law generally recognises that businesses have legitimate interests in:

protecting intellectual property;

recovering investment;

maintaining security;

protecting confidential information;

preserving commercial incentives.

Compulsory access is therefore normally associated with demanding legal conditions.

The IMS Health and Bronner authorities are particularly important in maintaining this balance.

35. The Future of Healthcare Data Competition

The competition implications will become increasingly significant as healthcare becomes more data-driven.

Future markets may combine:

EHR data + genomic data + medical imaging + AI + pharmaceutical research + insurance analytics + digital health applications.

This could produce highly integrated healthcare ecosystems.

A dominant undertaking could potentially control:

Data → infrastructure → AI → analytics → healthcare services

The principal competition challenge will therefore be preventing data control from becoming an enduring barrier to innovation while preserving incentives for healthcare companies to invest in data infrastructure.

Conclusion

Healthcare data monopolies present competition law with a problem fundamentally different from ordinary market concentration. The source of market power may not be factories, physical infrastructure or traditional capital, but control over information that competitors cannot easily reproduce.

The principal competition concerns are:

Denial of access to strategically important data;

exclusive data arrangements;

interoperability restrictions;

discriminatory data access;

self-preferencing;

data-driven vertical leveraging;

information exchange among healthcare competitors;

network effects and switching costs;

data-enabled AI entry barriers;

mergers producing excessive healthcare-data concentration.

The authorities in Indiana Federation of Dentists, U.S. Gypsum, Surescripts, IMS Health, Bronner, Microsoft, Google Shopping, Google Android, American Express, North Carolina Dental and Phoebe Putney collectively show that healthcare data can be both an efficiency-enhancing input and a potential source of competitive foreclosure.

The fundamental competition-law principle is therefore:

Possession of healthcare data is not itself unlawful. The antitrust concern arises when control over strategically important data, combined with market power, is used to exclude rivals, restrict interoperability, facilitate coordination, or prevent effective competition.